<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03898414</url>
  </required_header>
  <id_info>
    <org_study_id>autoimmune liver disease</org_study_id>
    <nct_id>NCT03898414</nct_id>
  </id_info>
  <brief_title>Patterns and Outcome of Autoimmune Related Liver Disease</brief_title>
  <official_title>Patterns and Outcome of Autoimmune Related Chronic Liver Disease : Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of the different patterns of autoimmune related chronic liver disease to assess the&#xD;
      prevalence of various types and outcome of treatment of autoimmune related chronic liver&#xD;
      disease&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmune liver diseases (AILD) are a group of immunologically induced hepatic damage that&#xD;
      are either hepatocellular or cholestatic. The hepatocellular forms are characterized by a&#xD;
      significant elevation of the serum alanine aminotransferase (ALT) and aspartate&#xD;
      aminotransferase (AST), as compared with the biliary enzymes,together with elevated serum&#xD;
      bilirubin Autoimmune hepatitis (AIH) is the typical example of hepatocellular autoimmune&#xD;
      liver diseases, but it can also be presented under a cholestatic pattern. Autoimmune&#xD;
      hepatitis has a scoring diagnostic system and respond in most cases to the treatment with&#xD;
      prednisolone and azathioprine. Primary biliary cirrhosis (PBC) is the second most common&#xD;
      autoimmune liver diseases , with a cholestatic presentation and characterized by positive&#xD;
      antimitochondrial antibody (AMA). It has an excellent response and long term outcome with the&#xD;
      administration of ursodeoxycholic acid (UDCA) Another autoimmune liver disease that is&#xD;
      thought to be a variant of PBC is the autoimmune cholangitis, being a disease that has&#xD;
      biochemical and histological features similar to PBC; but the AMA is negative. Primary&#xD;
      sclerosing cholangitis (PSC) is a rare entity of autoimmune liver disease that has a&#xD;
      cholestatic presentation and respond poorly to the treatment, with the ultimate progression&#xD;
      to advance liver cirrhosis in most patients Other forms of autoimmune liver disease include&#xD;
      the overlap syndromes (OS), which are diseases with mixed immunological and histological&#xD;
      patterns of two autoimmune liver disease the most commonly recognized one is AIH-PBC overlap&#xD;
      (AIH-PSC overlap is less common). The treatment of OS involves the trial of ursodeoxycholic&#xD;
      acid and different immunosuppressant.&#xD;
&#xD;
      The vast majority of studies examining the incidence and prevalence of autoimmune liver&#xD;
      disease have focused on PBC. Estimates of both disease incidence and prevalence vary quite&#xD;
      widely between studies of specific defined populations.&#xD;
&#xD;
      Primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH) and primary sclerosing&#xD;
      cholangitis (PSC) are chronic liver diseases that likely have an autoimmune basis to their&#xD;
      pathogenesis. Although significant strides have been made in the clinical management of these&#xD;
      conditions, their pathogenesis remains obscure. Understanding of various epidemiological&#xD;
      factors may shed light on predisposing or causative factors of these diseases There are&#xD;
      limited Egyptian studies available on prevalence and spectrum of autoimmune liver diseases in&#xD;
      cholestatic liver diseases, so the investigators will design this work to evaluate the&#xD;
      prevalence of autoimmune liver diseases in cholestatic liver diseases and clinical profile of&#xD;
      the various autoimmune liver diseases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of patterns of autoimmune chronic liver diseases</measure>
    <time_frame>2013-2019</time_frame>
    <description>Evaluation of patterns of autoimmune chronic liver diseasesupport and outcome of treagent of these diseases</description>
  </primary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Autoimmune Liver Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18-60 years old with autoimmune related chronic liver disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -Inclusion criteria :&#xD;
&#xD;
        Patients that will fulfill the following criteria will be enrolled:&#xD;
&#xD;
          1. Patients diagnosed as AIH According to the simplified criteria of AIH scoring&#xD;
&#xD;
          2. Patients diagnosed as PBC or PSC according to the Amiracan association of study of&#xD;
             liver disease (AASLD) - For all enrolled patients the presentation, treatment history,&#xD;
             and outcome of treatment will be evaluated.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
        1-- All patients with chronic liver disease other than autoimmune liver disease will be&#xD;
        excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yomna Abou Elwafa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Mohamed, Lecturer</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Mekky, Ass. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university hospitals</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Lee YM, Teo EK, Ng TM, Khor C, Fock KM. Autoimmune hepatitis in Singapore: a rare syndrome affecting middle-aged women. J Gastroenterol Hepatol. 2001 Dec;16(12):1384-9.</citation>
    <PMID>11851837</PMID>
  </reference>
  <reference>
    <citation>Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, Baldo V, Premoli A, Olivero F, Morello E, Durazzo M. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther. 2006 Oct 1;24(7):1051-7.</citation>
    <PMID>16984499</PMID>
  </reference>
  <reference>
    <citation>Kumagi T, Alswat K, Hirschfield GM, Heathcote J. New insights into autoimmune liver diseases. Hepatol Res. 2008 Aug;38(8):745-61. doi: 10.1111/j.1872-034X.2008.00366.x. Epub 2008 May 7.</citation>
    <PMID>18462376</PMID>
  </reference>
  <reference>
    <citation>Fallatah HI, Akbar HO, Qari YA. Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia. Saudi J Gastroenterol. 2010 Apr-Jun;16(2):95-9. doi: 10.4103/1319-3767.61235.</citation>
    <PMID>20339178</PMID>
  </reference>
  <reference>
    <citation>Hirschfield GM, Al-Harthi N, Heathcote EJ. Current status of therapy in autoimmune liver disease. Therap Adv Gastroenterol. 2009 Jan;2(1):11-28. doi: 10.1177/1756283X08098966.</citation>
    <PMID>21180531</PMID>
  </reference>
  <reference>
    <citation>Bogdanos DP, Gershwin ME. What is new in primary biliary cirrhosis? Dig Dis. 2012;30 Suppl 1:20-31. doi: 10.1159/000341118. Epub 2012 Oct 11. Review.</citation>
    <PMID>23075865</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Yomna Hammam Abou El-Wafa</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

